STOCKHOLM, Sweden, April 27, 2005 (PRIMEZONE) -- At the Annual General Meeting held in Biotage AB (corporate registration no. 556539-3138) on April 27, 2005, the following resolutions were passed, among others:
Appropriation of the company's result
The General Meeting resolved, in accordance with the proposal by the Board of Directors and the Managing Director, that no dividend shall be paid in respect of the financial year 2004 and that the company's accumulated loss shall be balanced on new account.
Board of Directors etc.
The General Meeting resolved, in accordance with the proposal by the Nomination Committee, to re-elect Jeff Bork, Borje Ekholm, Staffan Lindstrand, Ove Mattsson, Bjorn Odlander, Anders Rydin, Bengt Samuelsson and Mathias Uhlen as Board members and to elect Annika Espander as new Board member for the period until the end of the Annual General Meeting 2006. In accordance with the proposal by the Nomination Committee, the General Meeting further resolved to appoint Borje Ekholm as chairman of the Board. The previous Board member Bengt Falk and the previous deputy Board member Hans Engblom had notified that they decline re-election.
The newly elected Board member Annika Espander was born in 1964 and is employed as CEO of, and is also a board member of, Catella Healthcare AB.
About Biotage
Biotage is a global company active in life science research with strong technologies, a broad range of operations and a long-term view of the market. The company offers solutions, knowledge and experience in the areas of genetic analysis and medicinal chemistry. Customers include the world's top 30 pharmaceutical companies, 20 largest biotech companies and leading academic institutes. The company is headquartered in Uppsala and has offices in the US, Japan and several European countries. Biotage has approx. 230 employees and had sales of 367 MSEK in 2004. Biotage is listed on the Stockholm stock exchange. Website: www.biotage.com
Certain statements in this press release are forward-looking. These may be identified by the use of forward- looking words or phrases such as "believe," "expect," "intend," and "should," among others. These forward-looking statements are based on Biotage's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Biotage notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations), variability of operating results, the commercial development of the microwave synthesis and flash purification in the drug discovery market, DNA sequencing and genomics market, nucleic acid-based molecular diagnostics market, and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for Biotage's products (including seasonal fluctuations), difficulties in successfully adapting the Company's products to integrated solutions and producing such products, and the Company's ability to identify and develop new products and to differentiate its products from competitors.
This information was brought to you by Waymaker http://www.waymaker.net
The following files are available for download:
http://wpy.waymaker.net/client/waymaker1/WOLReleaseFile.aspx?id=93064&fn=wkr0001.pdf